- 米国企業
- IOVANCE BIOTHERAPEUTICS, INC.
IOVANCE BIOTHERAPEUTICS, INC.IOVA
時価総額
$21.3億
PER
2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | |
Research and development | 2 | - | - | 3 | 15 | 28 | 72 | 100 | 166 | 202 | 259 | 295 | 344 |
Cost of sales | - | - | - | - | - | - | - | - | - | - | - | - | 11 |
General and Administrative Expense | - | - | - | - | 12 | 26 | 21 | 28 | 41 | 60 | 84 | 104 | 107 |
Research and development | 2 | - | - | 3 | 15 | 28 | 72 | 100 | 166 | 202 | 259 | 295 | 344 |
Total costs and expenses | 22 | - | - | 12 | 28 | 54 | 93 | 128 | 207 | 262 | 343 | 399 | 462 |
General and Administrative Expense | - | - | - | - | 12 | 26 | 21 | 28 | 41 | 60 | 84 | 104 | 107 |
Total costs and expenses | - | - | - | - | - | - | - | - | - | - | - | - | 462 |
Total revenue | - | - | - | - | - | - | - | - | - | - | - | - | 1 |
Loss from operations | -21,218,318 | - | - | -12,040,369 | -28 | -54 | -93 | -128 | -207 | -262 | -343 | -399 | -461 |
Research and development | 2 | - | - | 3 | 15 | 28 | 72 | 100 | 166 | 202 | 259 | 295 | 344 |
Cost of sales | - | - | - | - | - | - | - | - | - | - | - | - | 11 |
General and Administrative Expense | - | - | - | - | 12 | 26 | 21 | 28 | 41 | 60 | 84 | 104 | 107 |
Research and development | 2 | - | - | 3 | 15 | 28 | 72 | 100 | 166 | 202 | 259 | 295 | 344 |
Total costs and expenses | 22 | - | - | 12 | 28 | 54 | 93 | 128 | 207 | 262 | 343 | 399 | 462 |
General and Administrative Expense | - | - | - | - | 12 | 26 | 21 | 28 | 41 | 60 | 84 | 104 | 107 |
Total costs and expenses | - | - | - | - | - | - | - | - | - | - | - | - | 462 |
Interest income, net | - | - | - | - | - | 1 | 1 | 5 | 9 | 2 | 0 | 3 | 13 |
Net Loss | -25,694,100 | -3,307,619 | -25,381,363 | -12,034,709 | -28 | -53 | -92 | -124 | -198 | -260 | -342 | -396 | -444 |
Net Loss before income taxes | - | - | - | - | - | - | - | - | - | - | - | - | -448 |
Income tax benefit | - | - | - | - | - | - | - | - | - | - | - | - | -3 |
Net Loss | -25,694,100 | -3,307,619 | -25,381,363 | -12,034,709 | -28 | -53 | -92 | -124 | -198 | -260 | -342 | -396 | -444 |
Loss from operations | -21,218,318 | - | - | -12,040,369 | -28 | -54 | -93 | -128 | -207 | -262 | -343 | -399 | -461 |
Earnings Per Share, Basic | - | - | - | - | - | - | - | - | - | - | -2.23 | -2.49 | -1.89 |
Interest income, net | - | - | - | - | - | 1 | 1 | 5 | 9 | 2 | 0 | 3 | 13 |
Net Loss | -25,694,100 | -3,307,619 | -25,381,363 | -12,034,709 | -28 | -53 | -92 | -124 | -198 | -260 | -342 | -396 | -444 |
Net Loss before income taxes | - | - | - | - | - | - | - | - | - | - | - | - | -448 |
Income tax benefit | - | - | - | - | - | - | - | - | - | - | - | - | -3 |
Net Loss | -25,694,100 | -3,307,619 | -25,381,363 | -12,034,709 | -28 | -53 | -92 | -124 | -198 | -260 | -342 | -396 | -444 |
Earnings Per Share, Diluted | - | - | - | - | - | - | - | - | - | - | -2.23 | -2.49 | -1.89 |
Earnings Per Share, Basic | - | - | - | - | - | - | - | - | - | - | -2.23 | -2.49 | -1.89 |
Earnings Per Share, Diluted | - | - | - | - | - | - | - | - | - | - | -2.23 | -2.49 | -1.89 |